Investor Presentation Q1 2023
113
Investor presentation
First three months of 2023
Region China at a glance.
Region China
Million
Diabetes trend
DKK
billion
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
First quarter of
2023
Sales
(mDKK)
Growth²
200
6%
14%
160
Total GLP-13
1,349
56%
50
30
100%
Long-acting insulin4
416
-25%
89.1%1
GLP-1
80%
Premix insulin5
1,310
-13%
120
20
20
Insulin
Fast-acting insulin
470
-27%
5.9%1
60%
Human insulin
175
391
-38%
80
164
141
40%
Total insulin
2,587
-22%
10
40
40
Other Diabetes care?
289
-13%
9.6%¹
OAD
20%
Diabetes care
4,225
-7%
0
2021
0
0%
Obesity care
53
46%
2030
2045
Feb
2018
Population with diabetes
Diabetes growth rate
Feb
2023
Diabetes & Obesity care
4,278
-6%
-GLP-1 MS
-Insulin MS
Rare disease8
OAD MS
183
27%
Total
4,461
-5%
Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021
Region China covers Mainland China, Taiwan, and Hong Kong
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of Feb 2023: Novo Nordisk 53%, Sanofi 15%,
Gan & Lee 0.1% and Eli Lilly 9%; Competitor GLP-1 value market shares, as of Feb 2023:
Novo Nordisk 67% and Eli Lilly 27%
OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT, Feb 2023 value figures
4
2 At constant exchange rates; 3 Comprises VictozaⓇ and OzempicⓇ;
Comprises Tresiba®, XultophyⓇ and Levemir®: 5 Comprises NovoMixⓇ and
Ryzodeg®: 6 Comprises NovoRapidⓇ; 7 Comprises Novo NormⓇ and needles; 8
Comprises SaxendaⓇ; 9 Comprises primarily Novo Seven®, Novo Eight® and
NorditropinⓇView entire presentation